Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation  by Ikezumi, Yohei et al.
Kidney International, Vol. 63 (2003), pp. 83–95
Adoptive transfer studies demonstrate that macrophages can
induce proteinuria and mesangial cell proliferation
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increase in urinary monocyte chemoattractant protein-1 (MCP-1)Adoptive transfer studies demonstrate that macrophages can
excretion.induce proteinuria and mesangial cell proliferation.
Conclusion. This study provides the first direct evidence thatBackground. Glomerular macrophage accumulation is a fea-
macrophages can induce renal injury in terms of proteinuriature of proliferative human and experimental glomerulonephri-
and mesangial cell proliferation.tis. However, our understanding of the role of macrophages
in the induction of renal injury is based upon indirect evidence
from depletion studies, most of which lack specificity for this
cell type. Therefore, an adoptive transfer approach was used Glomerular macrophage accumulation, first identified
to directly assess the potential of macrophages to induce renal in crescentic glomerulonephritis [1], is a common featureinjury.
in proliferative forms of human glomerulonephritis [2–4].Methods. Accelerated anti-glomerular basement membrane
The ability of macrophages to secrete a wide range of(anti-GBM) disease was induced in rats by immunization with
sheep IgG (day 5), followed by administration of sheep anti- factors that can cause tissue injury has led to the proposal
rat GBM serum (day 0), with animals killed on day 2. To that these cells actively participate in mediating renal
facilitate the adoptive transfer studies, immunized animals injury, rather than simply being a response to tissue dam-
were made leukopenic by cyclophosphamide (CyPh) given on age [5]. Analyses of renal biopsies have produced con-day 2. Bone marrow-derived (BM) or NR8383 macrophages
flicting results as to whether glomerular macrophage ac-were transferred by tail vein injection 24 hours after injection
cumulation does [3, 6, 7] or does not [4, 8, 9] correlateof anti-GBM serum, with animals killed 3 or 24 hours after
transfer. with the degree of proteinuria in glomerulonephritis.
Results. Pretreatment with CyPh prevented glomerular leu- However, there is general agreement that glomerular
kocyte accumulation and completely inhibited proteinuria, glo- macrophages are associated with glomerular lesions,
merular cell proliferation and hypercellularity in accelerated such as mesangial cell activation, mesangial expansion,anti-GBM disease. Adoptive transfer led to significant glomer-
hypercellularity and glomerulosclerosis [3, 7, 9–11].ular accumulation of BM or NR8383 macrophages within 3 hours
The pathogenic role of macrophages in renal injuryof injection, and this was still evident 24 hours later. Adoptive
transfer of BM or NR8383 macrophages induced proteinuria has been examined in animal models of kidney disease,
(63  16 BM vs. 5  2 mg/24 h CyPh control; P  0.001), particularly experimental anti-glomerular basement mem-
glomerular cell proliferation (5.1  1.2 BM vs. 0.5  0.1 brane (anti-GBM) disease. Time-course studies have
PCNA cells/gcs CyPh; P 0.001) and glomerular hypercellu- shown a temporal association between glomerular mac-larity (51.2  2.0 BM vs. 41.9  0.9 nuclei/gcs CyPh; P 
rophage accumulation and the induction of renal injury0.001). The degree of renal injury correlated with the number
in rat anti-GBM disease [12]. A variety of depletion stud-of transferred glomerular macrophages. Two-color immuno-
staining demonstrated that most glomerular proliferative cell ies have shown that a reduction in glomerular macrophage
nuclear antigen (PCNA) proliferating cells were OX-7 accumulation is associated with inhibition of proteinuria
mesangial cells. CyPh treatment did not prevent up-regulation [13–21]. However, caution must be used in interpreting
of glomerular intercellular adhesion molecule-1 (ICAM-1) and these studies since the methodologies employed havevascular cell adhesion molecule (VCAM-1) expression or an
broader effects than just depleting macrophages.
An alternative to depletion strategies and their inher-
ent limitations is the use of adoptive transfer to provideKey words: macrophage, adoptive transfer, proteinuria, proliferation,
mesangial, immunosuppression, glomerular disease. direct evidence that macrophages can induce renal in-
jury. A number of studies have shown that macrophagesReceived for publication May 20, 2002
transferred into animals can enter and accumulate withinand in revised form July 11, 2002
Accepted for publication August 8, 2002 the inflamed glomerulus [22–25]. However, the key issue
of whether transferred macrophages directly cause renal 2003 by the International Society of Nephrology
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injury, such as significant proteinuria and glomerular cell
proliferation, remains to be established.
Therefore, the aim of this study was to determine
whether macrophages directly induce renal injury. To
this end, we used adoptive transfer of macrophages in
a model of rat anti-GBM disease and quantified renal
injury in terms of proteinuria, glomerular cell prolifera-
tion and hypercellularity.
METHODS
Antibodies
The following mouse monoclonal antibodies (mAb)
Fig. 1. Protocol for adoptive transfer of macrophage-mediated renalwere used in this study: ED1, anti-rat CD68 that labels injury. Animals were immunized with sheep IgG (day 5) and then
monocytes and macrophages [26]; OX-42, anti-rat CD11b given a single administration of cyclophosphamide (day 2), which
resulted in 98% depletion of blood leukocytes at the time of injectionthat labels monocytes, most macrophage populations and
of anti-GBM serum (day 0). Macrophage transfer via tail vein injectionsome dendritic cells [27]; OX-1, anti-rat CD45 that labels was performed on day 1, and then animals were put into metabolic
all leukocytes [28]; OX-7, anti-Thy-1 antigen (CD90) that cages for a 24-hour urine collection before being killed (day 2). In
addition, some animals were killed 3 hours after adoptive transfer tolabels glomerular mesangial cells [29]; 1A29, anti-rat intra-
assess glomerular macrophage accumulation.cellular adhesion molecule-1 (ICAM-1; CD54) [30]; 5F10,
anti-vascular cell adhesion molecule-1 (VCAM-1; CD106)
[31]; R73, anti-rat  T-cell receptor non-polymorphic
determinant [32]; PC-10, anti-proliferating cell antigen tion was recovered and then cultured for five days in the
(PCNA) that labels cells in the G1, S, and G2 phases of presence of 20% L-cell conditioned medium as a source
the cell cycle (Dako Ltd, Glostrup, Denmark); and M744, of macrophage colony-stimulating factor. At the end of
anti-bromodeoxyuridine (BrdU) (Dako Ltd.). Peroxidase- the culture period, cells were at least 90% macrophages
and alkaline phosphatase-conjugated goat anti-mouse IgG, as judged by flow cytometric analysis and immunoperoxi-
peroxidase-conjugated mouse anti-peroxidase complexes dase using CD68 (ED1) and CD11b (OX-42) monoclonal
(PAP), and alkaline phosphatase-conjugated mouse anti- antibodies.
alkaline phosphatase complexes (APAAP) were purchased Macrophages were incubated with 50 g/mL BrdU
from Dako Ltd. Fluorescein isothiocyanate (FITC)-conju- during the last 24 hours of culture, washed three times in
gated rabbit anti-sheep Ig, FITC-conjugated rabbit anti-rat sterile saline, and then transferred to recipient animals.
IgG, and FITC-conjugated rabbit anti-rat C3 (Sigma- Immunohistochemistry staining showed that BrdU was
Aldrich, Castle Hill, NSW, Australia) were used in im-
incorporated into DNA in approximately 70% of the
munofluorescence staining.
cells and this label was used to identify cells after transfer
into recipient animals.Macrophage culture
NR8383 is a well characterized, semi-adherent macro- Accelerated anti-GBM disease
phage cell line derived from Sprague-Dawley rat lung
The experimental strategy is outlined in Figure 1. Ac-[33]. The NR8383 cell line was purchased from the Amer-
celerated anti-GBM disease was induced in inbred maleican Type Culture Collection (Manassas, VA, USA) and
Sprague-Dawley rats (150 to 180 g) by subcutaneouswas maintained in culture in Dulbecco’s modified Eagle’s
immunization with 5 mg sheep IgG in Freund’s completemedium/Ham’s F-12 medium (DMEM-F12; Gibco BRL,
adjuvant followed five days later by intravenous injectionGaithersburg, MD, USA) with 100 U/mL penicillin, 100
of sheep anti-rat GBM serum (day 0). Animals wereg/mL streptomycin and 10% fetal calf serum (FCS;
placed in metabolic cages on day 1 for a 24-hour urineTrace Biosciences, Melbourne, VIC, Australia).
collection and then killed. To deplete circulating leuko-Bone marrow-derived (BM) macrophages were pre-
cytes, animals were given an intraperitoneal injection ofpared by flushing dissected femurs and tibias of male
165 mg/kg cyclophosphamide (CyPh) on day 2. Thisinbred Sprague-Dawley rats using 0.2% ethylenedi-
caused 98% depletion of circulating leukocytes withinaminetetraacetic acid (EDTA) in sterile phosphate-buf-
48 hours (that is, at the time of anti-GBM serum injec-fered saline (PBS). Cells were teased apart, washed, and
tion), and this was maintained for three further days.resuspended in DMEM medium containing 100 U/mL
Macrophage transfer was performed in CyPh-treatedpenicillin, 100 g/mL streptomycin and 10% FCS. The
rats by an intravenous injection of NR8383 or BM macro-adherent stromal cell population was removed by a two
hour culture in petri dishes, and the non-adherent frac- phages 24 hours after administration of sheep anti-rat
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GBM serum. Animals were either killed three hours Immunoperoxidase staining for PCNA (PC10) and BrdU
(M744) was performed in 4 m paraffin sections of forma-after the transfer, or were placed in metabolic cages after
lin-fixed tissues using the same method with microwave-the transfer for 24 hours and killed afterwards. In some
based antigen retrieval.studies, animals received an intraperitoneal injection of
Two-color immunostaining was used to detect BrdUrat anti-sheep IgG serum (1 mL of pooled serum from
within the transferred macrophages. After staining forrats that had been immunized twice with 5 mg of sheep
BrdU using the M744 mAb in 4 m paraffin tissue sec-IgG) six hours after administration of sheep anti-rat
tions as described earlier, sections were given a secondGBM serum. Animals were kept in autoclaved cages to
round of microwave oven heating to block antibody cross-prevent infection.
reactivity, inactivate endogenous alkaline phosphatase and
Heterologous phase of rat anti-GBM disease enhance detection of the CD68 antigen [34]. Sections then
were blocked as above, drained, incubated with the ED1Heterologous phase anti-GBM disease was induced
mAb for 60 minutes, washed, and incubated sequentiallyin inbred male Sprague-Dawley rats by intravenous in-
with alkaline phosphatase-conjugated goat anti-mousejection of sheep anti-rat GBM serum (day 0). Animals
IgG and mouse APAAP complexes, and then developedwere placed in metabolic cages on day 1 for a 24-hour
with Fast Blue BB Salt (Ajax Chemicals, Melbourne,urine collection and then killed. Leukocyte depletion via
Australia).CyPh treatment and macrophage transfer was performed
The same methodology was used in two-color stainingthe same way as for accelerated anti-GBM disease.
to examine mesangial cell proliferation. Paraffin sections
(4 m) of methylcarn-fixed tissue were stained with theBiochemical analysis
OX-7 mAb using a three-layer immunoperoxidase method,Protein excretion in 24-hour urine collections was de-
microwaved and then stained for BrdU using the M744termined using the benzethonium chloride method. Con-
mAb using a three-layer immunoalkaline phosphatasecentrations of plasma and urine creatinine were mea-
method.sured using the standard Jaffe rate reaction (alkaline
The number of cells stained using ED1, R73 and OX-1picrate method). Whole blood cell counts were per-
mAb were counted in at least 50 glomerular cross-sec-formed on a Cell-Dyn 3500 automated cell counter (Ab-
tions (gcs) per animal on coded slides. Data are expressedbott Laboratories, Abbott Park, IL, USA) using heparin-
as the mean count  SD.ized blood collected from tail veins. All analyses were
performed by the Department of Biochemistry, Monash MCP-1 ELISA
Medical Centre. Twenty-four-hour urine samples were centrifuged, ali-
quoted and then stored at20	C. The level of monocyteHistopathology
chemoattractant protein-1 (MCP-1) in urine samples was
Tissues were fixed in 4% buffered formalin and then determined by a sandwich enzyme-linked immunosor-
embedded in paraffin. Sections (2 m) were stained with bent assay (ELISA) according to the manufacturer’s in-
periodic acid-Schiff (PAS) reagent and hematoxylin. structions (Pharmingen, San Diego, CA, USA). Rat urine
Glomerular hypercellularity was determined by counting samples (100 L) were assayed in a dilution range of
the number of nuclei in 30 full-sized glomerular cross- 1:2 to 1:64.
sections (gcs) per animal in PAS-stained sections.
Serum rat anti-sheep IgG antibody response
Immunohistochemistry
Circulating levels of rat IgG reactive with rabbit immu-
Three layer immunoperoxidase staining was used to noglobulin were quantified by a sandwich ELISA as de-
detect macrophages (ED1), T-cells (R73), total leukocytes scribed previously [35]. Briefly, 96-well plates were coated
(OX-1), ICAM-1 and VCAM-1 in cryostat sections (5m) overnight with normal sheep IgG, washed with 0.05%
of tissue fixed in 2% paraformaldehyde-lysine-periodate, Tween 20 in PBS, blocked with 1% bovine serum albu-
as previously described [34]. Antigen retrieval using 10 min (BSA), washed, incubated with varying dilutions of
minutes of microwave oven heating in 0.01 mol/L sodium rat serum for two hours, washed, incubated with peroxi-
citrate, pH 6.0 was performed on sections prior to ED1 dase-conjugated rabbit anti-rat IgG and color develop-
immunostaining. Sections were then blocked with 10% ment using the 3,3
,5,5
-tetramethyl benzidine (TMB)
FCS and 10% normal sheep serum in PBS for 20 minutes, substrate. The optical density was read at 490 nm on a
drained, incubated with the appropriate mouse mAb for Dynatec MR 5000 ELISA plate reader.
60 minutes, washed in PBS, and then endogenous peroxi-
Immunofluorescencedase inactivated by incubation in 0.3% H2O2 in methanol.
Sections then were washed in PBS, incubated with perox- Kidney deposition of sheep Ig, rat IgG and rat comple-
idase-conjugated goat anti-mouse IgG, washed in PBS, ment component C3 was determined by direct immuno-
incubated with mouse PAP complexes, and developed fluorescence staining. Sections (4 m) of snap frozen
tissue were blocked in 10% FCS and 10% rabbit serumwith 3,3-diaminobenzidine to produce a brown color.
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Table 1. Effects of cyclophosphamide (CyPh) treatment on rat accelerated anti-GBM disease
Normal Anti-GBM disease Anti-GBM disease  CyPh treatment
Renal injury
Proteinuria mg/24 h 4.21.1 177.878.4b 4.22.4c
Renal function
Serum creatinine lmol/L 60.77.0 59.84.6 54.76.0
Creatinine clearance mL/min 1.040.06 0.940.19 0.870.16
Glomerular histology
Proliferation PCNA cells/gcs 0.20.1 10.31.8b 0.50.1c
Cellularity nuclei/gcs 40.81.5 63.85.4b 41.80.8c
Glomerular leukocytes
Leukocytes OX-1 cells/gcs 0.500.14 15.591.43b 0.110.02c
Macrophages ED1 cells/gcs 0.430.09 13.272.37b 0.120.07c
T cells R73 cells/gcs 0.140.04 0.550.09b 0.030.01a,c
Blood leukocyte counts
Total white blood cells 103/lL 16.92.9 12.33.3b 0.0780.057b,c
Neutrophils 103/lL 1.30.2 3.51.6b 0.0050.004a,c
Lymphocytes 103/lL 14.12.7 7.82.0b 0.0610.052b,c
Monocytes 103/lL 0.490.12 0.530.25 0.0090.022b,c
Abbreviations are: GBM, glomerular basement membrane; PCNA, proliferating cell nuclear antigen; gcs, glomerular cross-section.
aP  0.05, bP  0.001 vs. normal group
cP  0.001 vs. disease group, by ANOVA with the Bonferroni’s post-test
Fig. 2. Glomerular histology of macrophage
adoptive transfer in rat anti-GBM disease. His-
tology was assessed on PAS stained 2 m for-
malin-fixed, paraffin sections. (a ) Normal rat
kidney. (b ) Control anti-GBM disease show-
ing glomerular hypercellularity and glomeru-
lar deposition of PAS stained material. (c )
Cyclophosphamide treatment of rat anti-GBM
disease prevents glomerular damage. (d) Adop-
tive transfer of 7  107 bone marrow-derived
macrophages into a cyclophosphamide treated
rat with anti-GBM disease results in glomeru-
lar hypercellularity and mild PAS stained de-
posits. Original magnification, 400.
for 30 minutes, drained, and incubated with appropriate group means, and then compared with the Bonferroni
multiple comparison test. Correlation analysis was per-FITC-conjugated rabbit polyclonal antibody. After
formed using the Pearson single correlation coefficient.washing, sections were mounted in 5% diazabicyclo[2.2.2]
All values were expressed as mean  SD.octane (Sigma-Aldrich) and examined under a fluores-
cence microscope.
RESULTSStatistical analysis
Cyclophosphamide pretreatment suppressesStatistical analysis was performed using GraphPad
accelerated anti-GBM diseasePrism (GraphPad Software, San Diego, CA, USA). Com-
parison between groups of animals was performed by In order to examine macrophage adoptive transfer in
anti-GBM disease, it was necessary to remove the contri-one-way analysis of variance (ANOVA) with individual
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Fig. 3. Immunohistochemistry assessment of
macrophage adoptive transfer in rat accelerated
anti-GBM disease. (a) Immunoperoxidase stain-
ing fails to detect glomerular ED1 macro-
phages in anti-GBM disease with cyclophos-
phamide (CyPh) treatment. (b ) Several ED1
macrophages (brown) are present within a glo-
merulus 3 hours after adoptive transfer of 7 
107 bone marrow-derived (BM) macrophages
into a CyPh treated rat with anti-GBM disease.
(c ) Glomerular ED1 macrophages (brown)
are still evident 24 hours after adoptive transfer
of BM macrophages into CyPh treated rats
with anti-GBM disease. (d ) Double immuno-
staining for ED1 (blue) and BrdU (brown nuclei;
arrowheads) confirms the donor origin of glo-
merular macrophages seen 3 hours after adop-
tive transfer of BM macrophages. Note that
not all ED1macrophages (blue) are sectioned
through the nucleus. (e ) Control accelerated
anti-GBM disease showing many proliferating
glomerular cells as identified by staining for
the proliferating cell nuclear antigen (PCNA,
brown nuclei). ( f ) CyPh treatment of anti-
GBM disease prevents the appearance of glo-
merular PCNA cells. (g ) Adoptive transfer
of 7 107 BM macrophages into CyPh treated
anti-GBM disease, induces the appearance of
glomerular PCNA cells (brown), and (h )
two-color staining identifies the PCNA cells
(gray-blue nuclei in this case) as mesangial cells
on the basis of OX-7 staining (brown) around
the PCNAnuclei (arrows). Sections in panels
a, b and d were counterstained with hematoxy-
lin. Original magnification, 400.
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bution of endogenous leukocytes. This was achieved by
treatment with a single dose of 165 mg/kg cyclophospha-
mide (CyPh) two days before administration anti-GBM
serum (Fig. 1). This resulted in98% reduction in white
blood cells at the time of anti-GBM serum administra-
tion (day 0), which was maintained until animals were
killed on day 2 (Table 1). CyPh treatment abolished
glomerular leukocyte accumulation and prevented renal
injury in accelerated anti-GBM disease in terms of pro-
teinuria, glomerular cell proliferation and glomerular
hypercellularity (Table 1). Glomerular pathology is mild
at this early stage of accelerated anti-GBM disease [12].
However, CyPh treatment completely prevented glo-
merular hypercellularity and glomerular deposition of
PAS stained material (Fig. 2). Renal function was un-
changed at day 2 in this disease model (Table 1).
Glomerular accumulation of transferred macrophages
Macrophages from two independent sources were
used in transfer studies; bone marrow-derived (BM) and
NR8383 macrophages. Significant numbers of BM or
NR8383 macrophages were evident within the glomeru-
lus three hours after tail vein injection into CyPh treated
rats with anti-GBM disease (Fig. 3). Quantitative analy-
sis found that administration of 5 107 BM macrophages
into a group of five animals with CyPh treated acceler-
ated anti-GBM disease resulted in 2.6  0.5 ED1 mac-
rophages/gcs at three hours after transfer, a 20-fold in-
crease compared to CyPh treated accelerated anti-GBM
disease without transfer (0.12  0.07 ED1 macro-
phages/gcs; P  0.001). There was a reduction in the
number of macrophages remaining in glomeruli by 24
hours after transfer (0.9  0.2 ED1 macrophages/gcs),
although this still represents a four- to fivefold increase
over animals without transfer (P  0.01). To confirm
the donor origin of glomerular macrophages, BM and
NR8383 macrophages were labeled in vitro with BrdU
prior to adoptive transfer. Double staining with ED1
and BrdU antibodies confirmed that glomerular macro-
phages were of donor origin (Fig. 3d).
Adoptive transfer of macrophage-mediated renal injury
Glomerular accumulation of BM or NR8383 macro-
phages in CyPh treated anti-GBM disease was depen-
dent upon the number of macrophages transferred (Fig.
4A). Adoptive transfer of BM or NR8383 macrophages
caused significant proteinuria and glomerular cell prolif-
eration in a dose-dependent fashion (Figs. 3 and 4). The
Fig. 4. Macrophage adoptive transfer induces renal injury in rat anti-
GBM disease. Accelerated anti-GBM disease was induced in control
rats or in cyclophosphamide treated rats. The cyclophosphamide treated
rats received adoptive transfer of 0, 3–5, or 8–10  107 NR8383 macro- injury assessed by 24-hour urinary protein excretion. (C ) Glomerular
phages or adoptive transfer of 0, 3–5, or 6–7 107 bone marrow-derived cell proliferation assessed by PCNA cells/gcs. (D ) Glomerular cellu-
(BM) macrophages. Animals were killed 24 hours after transfer and larity assessed by the number of nuclei/gcs. Data are expressed as the
renal injury assessed. (A ) Glomerular macrophage accumulation ex- mean of groups of 5 animals SD. Groups were compared by ANOVA
pressed as ED1 cells per glomerular cross-section (gcs). (B ) Renal using the Bonferroni post-test analysis.
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Fig. 5. Correlation between the glomerular
accumulation of transferred macrophages and
the severity of renal injury in rat anti-GBM
disease. The number of glomerular ED1
macrophages in animals given adoptive trans-
fer of NR8383 or bone marrow-derived macro-
phages was correlated with: (A, D) proteinuria;
(B, E ) PCNA cells per glomerular cross-
section (gcs); and (C, F ) glomerular cellularity
(nuclei/gcs) using the Pearson single correla-
tion coefficient (N  10).
number of proliferating glomerular cells was significantly Adoptive transfer led to the accumulation of many
greater than the number of transferred macrophages BM and NR8383 macrophages in the lung at 3 and 24
(Fig. 4); therefore, we examined whether this could be hours after injection. This occurred in both CyPh-treated
due to proliferation of intrinsic cells. Double immuno- anti-GBM disease and in normal rats, indicating that
staining demonstrated that mesangial cells accounted for pulmonary macrophage accumulation is not related to
most of the proliferating glomerular cells (Fig. 3h). Sig- anti-GBM disease. In addition, small numbers of trans-
nificant glomerular hypercellularity was seen with trans- ferred BM and NR8383 macrophages were evident in
fer of the highest dose of BM macrophages, but hypercel- the spleen. These macrophages were seen in the red
lularity was not evident using adoptive transfer with pulp, located around the lymphoid areas that showed
NR8383 macrophages (Figs. 2 and 4D). There was a marked involution due to cyclophosphamide treatment.
significant correlation between the number of trans-
ferred BM or NR8383 glomerular macrophages and the Mechanisms of glomerular accumulation in the
degree of proteinuria and glomerular cell proliferation, adoptive transfer model
however; only transfer of BM macrophages correlated
The number of glomerular macrophages obtainedwith glomerular hypercellularity (Fig. 5).
after adoptive transfer into CyPh treated acceleratedAs a control, the highest number of NR8383 or BM
anti-GBM disease was well below that seen in diseasemacrophages was transferred into normal rats. Transfer
without CyPh treatment. This simply may reflect thedid not result in glomerular macrophage accumulation
difference between a single injection of cells in the trans-and did not cause renal injury in normal rats (proteinuria,
fer model versus the constant supply of blood monocytes3.9  1.4 mg/24 h; glomerular cell proliferation, 0.35 
in the control disease group. However, we investigated0.08 PCNA cells/gcs; and glomerular cellularity, 41.7 
whether known mechanisms of glomerular macrophage2.1 cells/gcs; all P  not significant compared with the
normal group; Table 1). accumulation in rat anti-GBM disease, such as adhesion
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Fig. 6. Effects of cyclophosphamide (CyPh) treatment on glomerular expression of leukocyte adhesion molecules in rat anti-GBM disease.
Immunohistochemistry staining showing constitutive glomerular expression of ICAM-1 in normal rat glomeruli (a ), which is up-regulated in control
accelerated anti-GBM disease (b ). Up-regulation of glomerular ICAM-1 expression also is evident in CyPh treated anti-GBM disease (c ). Normal
rat glomeruli show little or no immunostaining for VCAM-1 (d ). There is substantial induction of glomerular VCAM-1 expression in control anti-
GBM disease (e ), which is largely unaffected by CyPh treatment ( f ). Original magnification, 400.
molecule expression and chemokine production [18, 19, the cellular immune response as shown by abrogation
of glomerular T-cell accumulation (Table 1).36, 37], were affected by CyPh treatment.
Administration of rat anti-sheep IgG serum to CyPh-Immunostaining of tissue sections showed up-regulation
treated anti-GBM disease reconstituted the humoral im-of glomerular intercellular adhesion molecule-1 (ICAM-1,
mune response as shown by glomerular deposition of ratCD54) and vascular adhesion molecule-1 (VCAM-1,
IgG and C3 (Fig. 7). Under these conditions, there wasCD106) expression in control anti-GBM disease com-
a twofold increase in glomerular accumulation of trans-pared to normal rat kidney (Fig. 6). Up-regulation of
ferred BM macrophages and a twofold increase in theboth ICAM-1 and VCAM-1 was still evident in CyPh
severity of proteinuria, glomerular cell proliferation andtreated anti-GBM disease (Fig. 6). A marked increase
hypercellularity (Fig. 8).in urine levels of the chemokine monocyte chemotactic
protein-1 (MCP-1) was evident in control anti-GBM dis- Macrophage adoptive transfer reconstitutes renal
ease (36.2  17.7 vs. 6.7  1.2 ng/mL in normal rats; injury in the heterologous phase of anti-GBM disease
P  0.01), and this was unchanged with CyPh treatment
Suppression of the humoral and cellular immune re-of anti-GBM disease (34.1  5.0 ng/mL).
sponse by CyPh treatment effectively changed this model
Accelerated anti-GBM disease in control rats exhib- of accelerated anti-GBM disease from one of autologous
ited a humoral immune response to the immunizing anti- phase injury to one of heterologous phase injury. How-
gen (sheep IgG) as shown by glomerular deposition of rat ever, renal injury in the heterologous phase of anti-GBM
IgG and C3 (Fig. 7 a-c), and high levels of rat antibodies disease is thought to be mediated by neutrophils rather
against sheep IgG in the serum, which were readily de- than by macrophages. To examine this important point,
tected at a 1 in 10,000 dilution. In contrast, CyPh treat- we performed a separate study of macrophage adoptive
ment of accelerated anti-GBM disease prevented glo- transfer in the heterologous phase of anti-GBM disease.
merular deposition of rat IgG and C3, but had no effect As shown in Figure 8, CyPh treatment of the heterolo-
upon the deposition of sheep IgG (Fig. 7 d-f). There was gous phase of anti-GBM disease abrogated glomerular
also a lack of detectable serum antibodies against sheep macrophage accumulation and prevented proteinuria,
glomerular cell proliferation and glomerular hypercellu-IgG in CyPh-treated rats. CyPh treatment also inhibited
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Fig. 7. Immunofluorescence staining of glomerular deposition of humoral immune reactants in rat anti-GBM disease. Anti-GBM disease induced
in a control animal shows (a ) strong linear deposition of sheep anti-GBM antibody, (b ) linear deposition of rat IgG, and (c ) patchy linear
deposition of rat C3. Anti-GBM disease induced in a cyclophosphamide (CyPh) treated animal shows (d ) strong linear deposition of sheep anti-
GBM antibody, (e ) absence of rat IgG, and ( f ) absence of rat C3. Anti-GBM disease induced in a CyPh treated animal given passive transfer of
rat anti-sheep IgG serum shows (g ) strong linear deposition of sheep anti-GBM antibody, (h ) linear deposition of rat IgG, and (i ) patchy linear
deposition of rat C3. Original magnification, 400.
larity. Adoptive transfer of BM macrophages to CyPh phages can induce renal injury such as proteinuria, but
direct proof has been lacking. Studies of human glomeru-treated, heterologous phase anti-GBM disease resulted
lonephritis have produced conflicting results as to whetherin glomerular macrophage accumulation and the induc-
glomerular macrophage accumulation correlates withtion of proteinuria and glomerular cell proliferation that
proteinuria [3, 4, 6–9]. This is not surprising given thewas equivalent to that seen in control heterologous phase
inherent difficulties of these studies, such as being limitedanti-GBM disease without CyPh treatment (Fig. 9).
to analysis at a single time-point, and variation in the
patient populations examined. Time-course studies in
DISCUSSION animal models of glomerulonephritis have shown clear
To our knowledge, this study provides the first direct associations between macrophage accumulation and in-
evidence that macrophages can induce renal injury. duction of proteinuria [12]. In addition, macrophage de-
Adoptive transfer using two independent macrophage pletion using X-irradiation [13, 14], anti-macrophage sera
populations directly demonstrated macrophage-medi- [15, 16], lipid-encapsulated drugs [17], and blockade of
ated proteinuria, mesangial cell proliferation and hyper- chemokines such as MCP-1 and osteopontin [18–21] can
cellularity in rat anti-GBM disease. prevent the induction of proteinuria in models of anti-
GBM disease, puromycin aminonucleoside nephrosis andA body of evidence supports the postulate that macro-
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Heymann nephritis. However, these studies have inherent
problems in verifying that inhibition of proteinuria is
solely due to macrophage depletion. For example, X-irra-
diation affects all proliferating cells, the specificity of poly-
clonal anti-macrophage sera is difficult to characterize,
lipid-encapsulated drugs can deplete complement and
inhibit glomerular neutrophil accumulation [38, 39], and
MCP-1 and osteopontin also are involved in T-cell recruit-
ment and activation [19, 20, 40]. In contrast, the current
study used macrophage adoptive transfer to induce renal
injury.
Two different macrophage populations were used in
the transfer studies. BM macrophages are a heterogeneous
population that contains a minor component (10%) of
other cell types. We don’t believe that these other cell
types contributed to renal injury in the transfer model,
since virtually all BrdU-labeled cells in glomeruli were
double stained with the macrophage marker ED1. In
addition, the BM macrophage culture was not exposed
to the sheep IgG antigen. Importantly, renal injury was
induced by the NR8383 macrophage cell line in a manner
very similar to that seen with BM macrophages. With the
transfer of similar cell numbers, both BM and NR8383
macrophages induced proteinuria and glomerular cell
proliferation. Indeed, the degree of proteinuria and glo-
merular cell proliferation was directly proportional to
the number of transferred glomerular macrophages. The
main difference between the two cell types is in the
efficiency in glomerular accumulation. Transfer of BM
macrophages consistently resulted in a greater number
of glomerular macrophages compared to NR8383 cells.
This was reflected in the higher levels of proteinuria and
glomerular cell proliferation. However, when compared
to the actual number of transferred glomerular macro-
phages, the degree of renal injury was very similar for
both macrophage types. The only other difference be-
tween the two macrophage populations was that BM
macrophages, but not NR8383 macrophages, induced
glomerular hypercellularity. There was a trend toward
glomerular hypercellularity with transfer of the highest
number of NR8383 macrophages, suggesting that trans-
fer of greater numbers of NR8383 macrophages into the
glomerulus may result in hypercellularity.
The role of macrophages as a cause or effect in the
development of mesangial cell proliferation and glomer-
ulosclerosis has yet to be established [41]. Macrophages
may directly stimulate mesangial cell proliferation through
the production of mesangial cell growth factors such as
Fig. 8. Contribution of the humoral immune response to macrophage-
mediated renal injury in rat anti-GBM disease. Accelerated anti-GBM
disease was induced in groups of 6 cyclophosphamide-treated rats that
were given rat anti-sheep IgG serum (RatShIg Ab) or control rat section (gcs). (B ) Renal injury assessed by 24-hour urinary protein
serum (Rat Ctl Ab), with or without adoptive transfer of 8–10  107 excretion. (C ) Glomerular cell proliferation assessed by PCNA cells/
bone marrow-derived macrophages (BM-Mφ). Animals were killed 24 gcs. (D ) Glomerular cellularity assessed by the number of nuclei/gcs.
hours after transfer and renal injury assessed. (A ) Glomerular macro- Data are expressed as the mean of groups of 6 animals  SD. Groups
phage accumulation expressed as ED1 cells per glomerular cross- were compared by ANOVA using the Bonferroni post-test analysis.
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platelet-derived growth factor, interleukin-1, and basic
fibroblast growth factor [42–44]. Studies in human glo-
merulonephritis support a role for macrophages in pro-
moting mesangial hypercellularity and the development
of glomerulosclerosis [10, 45]. In addition, the appearance
of glomerular macrophages precedes mesangial hyper-
cellularity and glomerulosclerosis in experimental mod-
els of glomerulonephritis [7, 46, 47]. The use of X-irradia-
tion has suggested that macrophages promote mesangial
cell proliferation and the development of glomeruloscle-
rosis in puromycin aminonucleoside nephrosis and renal
ablation [7, 48]. In contrast, macrophage depletion in
rat anti-Thy-1 mesangial proliferative nephritis did not
affect mesangial cell proliferation [38], arguing against
a direct role for macrophages in this process. However,
mesangial cell proliferation following severe mesangial
lysis—a situation rarely seen in human glomerulonephri-
tis—may operate via different mechanisms compared to
mesangial cell proliferation induced in an intact glomeru-
lus. The current studies using adoptive transfer demon-
strate that mesangial proliferation in rat anti-GBM dis-
ease is macrophage-dependent. However, we cannot
determine whether this mesangial proliferation operates
directly via macrophage-derived growth factors, or if
it is an indirect response to glomerular injury. Further
studies are required to address this important question.
Glomerular accumulation of transferred macrophages
was dependent upon deposition of sheep anti-GBM anti-
bodies, since no accumulation or renal injury was evident
with macrophage transfer into normal animals. However,
macrophage accumulation was independent of a cellular
or humoral immune response, both of which were abol-
ished by CyPh treatment. Up-regulation of molecules in-
volved in glomerular macrophage recruitment (ICAM-1,
VCAM-1, MCP-1) also was dependent upon glomerular
deposition of sheep IgG and was not significantly af-
fected by CyPh treatment, suggesting a role for these
molecules in glomerular accumulation of transferred
macrophages. However, an additional role for the hu-
moral immune response in glomerular macrophage re-
cruitment was clearly demonstrated. Reconstitution of the
autologous humoral immune response in CyPh-treated
animals by passive administration of rat anti-sheep IgG
serum caused a twofold increase in the glomerular accu-
mulation of transferred macrophages, with a propor-
tional increase in the severity of proteinuria, glomerular
cell proliferation and hypercellularity.
Fig. 9. Adoptive transfer of macrophage-mediated renal injury in the
An interesting aspect of the study was the rapid disap-heterologous phase of rat anti-GBM disease. Anti-GBM disease was
induced in groups of 6 unprimed rats that had either no treatment pearance of macrophages from the glomerulus between
(disease control), cyclophosphamide treatment (CyPh), or CyPh treat- 3 and 24 hours after transfer. This is presumably the
ment plus adoptive transfer of 9–10  107 bone marrow-derived macro-
phages (BM-Mφ). Animals were killed 24 hours after transfer and renal
injury assessed. (A ) Glomerular macrophage accumulation expressed
as ED1 cells per glomerular cross-section (gcs). (B ) Renal injury
assessed by 24-hour urinary protein excretion. (C ) Glomerular cell
proliferation assessed by PCNA cells/gcs. (D ) Glomerular cellularity of groups of 6 animals  SD. Groups were compared by ANOVA
assessed by the number of nuclei/gcs. Data are expressed as the mean using the Bonferroni post-test analysis.
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